A number of adeno-associated virus (AAV)-based gene therapy products have entered
clinical development, with a few also reaching marketing approval. However, as our …

Gene therapy has proven to be extremely beneficial in the management of a wide range of
genetic disorders for which there are currently no or few effective treatments. Gene transfer …

Biodistribution of self-complementary adeno-associated virus-9 (scAAV9)–chicken β-actin
promoter–green fluorescent protein (GFP) was assessed in juvenile cynomolgus macaques …

This article reviews the presentation given at the 2023 annual meeting of the Society of
Toxicologic Pathology (STP) on liver toxicity observed with adeno-associated viral vector …

Dorsal root ganglia (DRG), trigeminal ganglia (TG), other sensory ganglia, and autonomic
ganglia may be injured by some test article classes, including anti-neoplastic …

Adeno-associated virus (AAV) gene therapy vectors are an accepted platform for treating
severe neurological diseases. Test article (TA)-related and procedure-related …

Certain biopharmaceutical products consistently affect dorsal root ganglia, trigeminal
ganglia, and/or autonomic ganglia. Product classes targeting ganglia include antineoplastic …

Biotherapeutic modalities such as cell therapies, gene therapies, nucleic acids, and proteins
are increasingly investigated as disease-modifying treatments for severe and life …

Adeno-associated virus (AAV)-based vectors are the most frequently used platform for
retinal gene therapy. Initially explored for the treatment of loss-of-function mutations …

Viral nanoparticles (VNPs) have emerged as crucial tools in the field of biomedicine.
Leveraging their biological and physicochemical properties, VNPs exhibit significant …